Detalhe da pesquisa
1.
Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.
Diabetes Care
; 29(12): 2670-5, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17130203
2.
[Microalbuminuria and urinary albumin excretion: clinical practice guidelines]. / Microalbuminurie et excrétion urinaire d'albumine: recommandations pour la pratique clinique.
Nephrol Ther
; 3(6): 384-91, 2007 Oct.
Artigo
em Francês
| MEDLINE | ID: mdl-17919641
3.
The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients.
J Nephrol
; 17(1): 66-75, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15151261
4.
Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
Nephrol Dial Transplant
; 20(6): 1103-9, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15855214
5.
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
J Am Soc Nephrol
; 16(10): 3027-37, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16120823
6.
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Nephrol Dial Transplant
; 18(10): 2059-66, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-13679481
7.
Patient referral is influenced by dialysis centre structure in the Diamant Alpin Dialysis cohort study.
Nephrol Dial Transplant
; 19(9): 2341-6, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15252154